NCT06488950

A Study of TIL in Advanced Solid Tumors (DFGD)

A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101/203 TIL) in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Shanghai Juncell Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Conditions

• Advanced Solid Tumor
• Tumor Infiltrating Lymphocytes
• Treatment Side Effects
• Effects of Immunotherapy

Interventions

Type	Name	Description
BIOLOGICAL	GC203 TIL(gene-edited TIL) or autologous TILs	the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample

Timeline

• Start date: 2023-04-01
• Primary completion: 2026-06-30
• Completion: 2027-06-30
• First posted: 2024-07-05
• Last updated: 2025-12-16

Locations

1 site across 1 country: China